Analysis: The Baseline Systemic Immune-Inflammation Index and the Innovative FLIPI-SII Model as Predictors of POD24 and Long-Term Outcomes in Grade 1–3a Follicular Lymphoma

By
Guilan Cheng
Kewei Yang
Dan He
Yue Liu
Hongmiao Li
Liangying Zhang
Qingxian Jia
Yuanping Yin
Zhihan Zhao
August 26, 2026

Frontiers In Immunology

1

Yu et al. developed the FLIPI-SII model by adding the systemic immune-inflammation index to the Follicular Lymphoma International Prognostic Index.
2

The FLIPI-SII model predicts progression of disease within 24 months and long-term survival in patients with grade 1–3a follicular lymphoma.
3

Elevated baseline systemic immune-inflammation index is associated with poorer overall and progression-free survival in treated patients.
4

FLIPI-SII serves as a prognostic stratification tool, but its role in treatment selection remains unproven and requires further investigation.
5

External validation of FLIPI-SII across multiple centers supports its generalizability, but further assessment is needed for consistent risk prediction.

Original Source(s)

Frontiers In Immunology

Commentary: Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1–3a follicular lymphoma

by Guilan Cheng, Kewei Yang, Dan He, Yue Liu, Hongmiao Li, Liangying Zhang, Qingxian Jia, Yuanping Yin, Zhihan Zhao
August 26, 2026

Related Content

Nature Medicine

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Roswell Park Comprehensive Cancer Center

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

by
August 26, 2026
3 min

Nature Cancer